GSK enters the competition for RSV vaccine with phase 3 results
There are currently no authorised vaccinations for Respiratory Syncytial Virus (RSV) anywhere in the world.
There are currently no authorised vaccinations for Respiratory Syncytial Virus (RSV) anywhere in the world.
These are the weekly disruptions seen in the healthcare industry from last week.
Gilead’s Trodelvy, a breast cancer medicine, makes a comeback as it wins FDA priority review on the application for highly pretreated HR-positive, HER2-negative breast cancer.
Lybrido, an oral tablet from Freya Pharma Solutions, will enter Phase III studies to treat female sexual interest/arousal issue (FSIAD) after being in development for almost a decade.
These are the weekly disruptions seen in the healthcare industry from last week.
While other pharma companies are entering Singapore, owing to its far-sightedness, Merck is expanding by establishing a new manufacturing facility.
Amylyx’s amyotrophic lateral sclerosis (ALS) drug, marketed as Relyvrio, has been approved by the FDA for the treatment of ALS in adults at a cost of $158,000 per year.
These are the weekly disruptions seen in the healthcare industry from last week.
Bora Pharmaceuticals joins hands with TaiRX, a Taiwan-based company focused on drug development, to formulate CVM-1118, an anticancer drug.
As Ireland proceeds ahead to become the hub of pharma manufacturing projects, Ipsen becomes the latest company to hop on the bandwagon.
There are currently no authorised vaccinations for Respiratory Syncytial Virus (RSV) anywhere in the world.
These are the weekly disruptions seen in the healthcare industry from last week.
Gilead’s Trodelvy, a breast cancer medicine, makes a comeback as it wins FDA priority review on the application for highly pretreated HR-positive, HER2-negative breast cancer.
Lybrido, an oral tablet from Freya Pharma Solutions, will enter Phase III studies to treat female sexual interest/arousal issue (FSIAD) after being in development for almost a decade.
These are the weekly disruptions seen in the healthcare industry from last week.
While other pharma companies are entering Singapore, owing to its far-sightedness, Merck is expanding by establishing a new manufacturing facility.
Amylyx’s amyotrophic lateral sclerosis (ALS) drug, marketed as Relyvrio, has been approved by the FDA for the treatment of ALS in adults at a cost of $158,000 per year.
These are the weekly disruptions seen in the healthcare industry from last week.
Bora Pharmaceuticals joins hands with TaiRX, a Taiwan-based company focused on drug development, to formulate CVM-1118, an anticancer drug.
As Ireland proceeds ahead to become the hub of pharma manufacturing projects, Ipsen becomes the latest company to hop on the bandwagon.
According to Business Wire, global Healthcare Industry will be worth $12T by 2022. Healthcare is vast and highly fragmented with a mix of public and private players. It comprises patients and healthcare providers such as hospitals, pharmaceuticals, and related life sciences.
Digitisation and Post-Covid world are set to transform the healthcare industry in the coming decade. Our weekly business newsletter covers innovations and disruptions in the Healthcare industry with global coverage.
HealthGeniuses is managed by IndustryGeniuses (A place where industries meet innovation). We are rolling out content platforms for the world’s hottest industries such as Food & Grocery Retail, Consumer Goods and Healthcare. For each of these key industries, we support Tech Startups and Industry Disruptors as they roll out next generation digital initiatives.
IndustryGeniuses team brings practical domain knowledge of working with 300+ tech startups and brands over the past decade.